Long-term safety and efficacy study of intranasal ipratroprium bromide

1990 ◽  
Vol 104 (2) ◽  
pp. 123-125 ◽  
Author(s):  
C. A. Milford ◽  
T. A. Mugliston ◽  
V. J. Lund ◽  
I. S. Mackay
Keyword(s):  
Side Effects ◽  
Open Trial ◽  
Systemic Effects ◽  
Efficacy Study ◽  
Safety And Efficacy ◽  
Treatment Side Effects ◽  
Main Complaint ◽  
One Year

AbstractForty patients presenting with watery rhinorrhoea as their main complaint were entered in an open trial of long-term intranasal ipratroprium bromide. Fourteen of these (35 per cent) found it to be beneficial and completed one year of treatment. Side-effects were seen in 28 patients (70 per cent) but these were local and mild in nature. All resolved during the trial as patients adjusted the dosage to individual severity and frequency of symptoms. No significant systemic effects were noted during the course of therapy. Ipratroprium is a useful drug in the treatment of watery rhinorroea and appears safe for long-term use.

scholarly journals AAV-Mediated Gene Therapy for Galactosialidosis: A Long-term Safety and Efficacy Study

2021 ◽  
Author(s):  
Huimin Hu ◽  
Rosario Mosca ◽  
Elida Gomero ◽  
Diantha van de Vlekkert ◽  
Yvan Campos ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Efficacy Study ◽  
Safety And Efficacy

scholarly journals Evaluating the Safety and Efficacy of a Highly Viscous 33-mg/mL Hyaluronic Acid Volumizing Filler in the Treatment of Facial Wrinkles: An Open-Labeled, Clinical Trials

2019 ◽  
Vol 8 ◽  
pp. e1148
Author(s):  
Elnaz Razavian ◽  
Setareh Tehrani
Keyword(s):  
Hyaluronic Acid ◽  
High Volume ◽  
Soft Tissue Augmentation ◽  
Nodule Formation ◽  
Safety And Efficacy ◽  
Significant Correction ◽  
Clinically Significant ◽  
One Year ◽  
First Time

Background: The 33-mg/mL hyaluronic acid (HA) formulation is a highly concentrated, cross-linked, cohesive, smooth, and completely reversible volumizing filler approved by Conformité Européene. For the first time, we aimed to evaluate the long-term efficacy and safety of the 33-mg/mL HA filler for soft tissue augmentation in the treatment of facial wrinkles. Materials and Methods: After optimal wrinkle correction was achieved in the patients undergoing treatment by injecting the 33-mg/mL HA filler at the injection site plus one touch-up at a 2-week interval, the safety and efficacy of the filler were assessed on the 5-point Facial Volume Loss Scale through the 1-year study period. Patients were evaluated daily for 14 days and after 6 and 12 months post-treatment. Results: A total of 86 subjects were treated. The mean wrinkle scores of the patients were 3.95+0.79 (range of 3-5) before treatment, 2.3+0.94 (range 1-5) six months after treatment, and 2.93+1.29 (range of 1-5) one year after treatment. Clinically significant mean wrinkle correction (P=0.001) was still evident at>12 months of treatment through 33-mg/mL HA formulation. A clinically significant correction at>12 months after treatment was maintained by 79% of patients. Nodule formation and swelling were more frequent when the 33-mg/mL HA filler was used compared with the use of less concentrated HA fillers. One patient developed angioedema-like swelling and induration last few months. Conclusion: The 33-mg/mL HA filler can provide long-term correction lasting for one year or more. Adverse effects, especially swelling and nodule formation were more common in this filler compared with less concentrated HA fillers. The side effects were correlated with the volume of the injected filler. We recommend using this concentration with low volume or combining high volume with lower concentration. [GMJ.2019;8:e1148]

scholarly journals One-Year Visual and Refractive Outcomes following LASIK for Myopia and Myopic Astigmatism with MEL 90 versus Schwind Amaris 750S Excimer Laser: A Comparative Study

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Sheetal Brar ◽  
Dishitha P. Rathod ◽  
C. R. Roopashree ◽  
Sri Ganesh
Keyword(s):  
Comparative Study ◽  
Clinical Outcomes ◽  
Excimer Laser ◽  
Infectious Keratitis ◽  
Safety And Efficacy ◽  
Refractive Outcomes ◽  
The Mean ◽  
One Year ◽  
Myopic Astigmatism

Purpose. To compare clinical outcomes following LASIK for myopia performed with MEL 90 vs. Schwind Amaris 750S excimer laser. Methods. Data were collected retrospectively for patients who underwent Femto-LASIK, using the MEL 90 and Schwind Amaris 750S excimer laser for correction of myopia and myopic astigmatism within the range of −1.00 to −10.00 D SE from January 2013 till June 2018. Outcomes were analysed at 12 months for safety, efficacy, enhancement rate, and long-term complications. Results. A total of 328 eyes of 328 patients were analysed. One hundred and sixty-three eyes were treated with Schwind Amaris and the remaining 165 eyes with the MEL 90 laser. Twelve months postoperatively, the mean UDVA, CDVA, residual SE, and cylinder in the Amaris group were −0.10 ± 0.09 logMAR, −0.14 ± 0.06 logMAR, −0.21 ± 0.22 D, −0.13 ± 0.18 D versus −0.05 ± 0.07 logMAR, −0.09 ± 0.08 logMAR, −0.23 ± 0.23 D, and −0.14 ± 0.21 D for the MEL 90 group ( p values >0.05). For the Amaris group, safety and efficacy indices were 1.12 and 1.02, whereas for the MEL 90 group, these indices were 1.08 and 1.00, respectively. No eye in either group had any postop flap-related complications, infectious keratitis, diffuse lamellar keratitis, or keratectasia. Two eyes in the Amaris and 4 eyes in MEL 90 group required enhancement for the progression of myopia. Conclusion. At 12 months, both Schwind Amaris 750S and MEL 90 lasers demonstrated comparable clinical outcomes for myopic LASIK in a single surgeon setting.

scholarly journals EP20 Long term safety and efficacy of denosumab and zoledronate

Rheumatology ◽  
2020 ◽  
Vol 59 (Supplement_2) ◽  
Author(s):  
Ziad Alkutobi ◽  
Deena Laila ◽  
Mohammad Tariq
Keyword(s):  
Side Effects ◽  
Neck Of Femur ◽  
Dxa Scan ◽  
Safety And Efficacy ◽  
Oral Bisphosphonate ◽  
Retrospective Audit ◽  
Number Of Patients ◽  
Gastrointestinal Side Effects ◽  
To Receive

Abstract Background Denosumab and zoledronate are increasingly prescribed for primary and secondary osteoporosis long-term management. Methods A retrospective audit was conducted at Basildon Hospital during 2012-2019 using the NICE guidelines standards to evaluate the long term safety and efficacy of denosumab and zoledronate. Number of patients was 84, diagnosed with osteoporosis or osteopenia, 34 of them received 10 or more denosumab injections and 50 patients planned to receive 5 zoledronate infusions (9 patients received 5 and 38 patients received 4). Results Forty percent of the patients were at their 8th decade followed by 28.57% and 21.42 % at their 9th and 7th decades respectively. More than 90% were Caucasian females. Primary prevention was in 39.28% and secondary prevention in 60.71%. The commonest sites of fracture were the wrist and vertebrae at 34.37% for each; followed by the neck of femur and humerous at 12.5% for each. Denosumab was the 1st, 2nd, 3rd or 4th line of treatment in 9.52%, 13.09%, 16.66% and 1.19% respectively; whereas zoledronate was the 1st, 2nd or 3rd line of treatment in 13.09%, 40.47% and 5.95% respectively. The commonest reason for choosing denosumab as the first line was chronic kidney disease, whereas the reason for choosing it as the 2nd or 3rd line was inefficacy of bisphosphonate in 69% or gastrointestinal side effects in 14%. Zoledronate was chosen in all cases because of intolerability to oral bisphosphonate or gastrointestinal side effects. Repeat DXA scan was performed after the 5th, 10th denosumab injections and the 3rd zoledronate infusions. After the 5th Denosumab, DXA scan showed improvement or stability in 100% and 85.29% at the spine and hip respectively whilst deterioration was seen in 14.7% at the hip. After the 10th denosumab, the rate of improvement or stability at the spine was reduced to 88.23% and decline was seen in 2.94%. At the hip area, 73.52% continued to show improvement or stability, whilst 17.66 % showed deterioration. After the 3rd zoledronate, 98% and 88% showed improvement or stability at the spine and hip respectively whilst deterioration seen in 2% and 12% at the spine and hip respectively. One patient on zoledronate experienced dental issues after the 4th injection and stopped treatment. There were no jaw osteonecrosis, no new fractures and no significant side effects with either denosumab or zoledronate. Ninety percent of patients who completed 10 denosumab injections were planned to continue for another 5 injections. Conclusion After the period of 3-5 years, denosumab and zoledronate were well tolerated and BMD was either stable or improved at both spinal and hip sites. There were few cases of deterioration mainly at the hip area with both zoledronate and denosumab. Future researches are needed to stratify guidelines on discontinuation of denosumab. Disclosures Z. Alkutobi None. D. Laila None. M. Tariq None. A. Nandagudi None.

Multicenter long-term safety and efficacy study of vigabatrin for refractory complex partial seizures: An update

Neurology ◽  
1991 ◽  
Vol 41 (3) ◽  
pp. 363-363 ◽  
Author(s):  
T. R. Browne ◽  
R. H. Mattson ◽  
J. K. Penry ◽  
D. B. Smith ◽  
D. M. Treiman ◽  
...  
Keyword(s):  
Efficacy Study ◽  
Partial Seizures ◽  
Complex Partial Seizures ◽  
Safety And Efficacy

ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation*

2007 ◽  
Vol 35 (6) ◽  
pp. 1457-1463 ◽  
Author(s):  
Pierre-Francois Laterre ◽  
Edward Abraham ◽  
Jonathan M. Janes ◽  
Benjamin L. Trzaskoma ◽  
Nancy L. Correll ◽  
...  
Keyword(s):  
Severe Sepsis ◽  
Drotrecogin Alfa ◽  
Early Stage ◽  
Efficacy Evaluation ◽  
Safety And Efficacy ◽  
Drotrecogin Alfa Activated ◽  
Long Term Follow Up ◽  
One Year

scholarly journals Long-term follow-up of the use of maintenance antibiotic therapy for chronic antibiotic-dependent pouchitis

2018 ◽  
Vol 9 (2) ◽  
pp. 154-158 ◽  
Author(s):  
Jonathan P Segal ◽  
Stephanie X Poo ◽  
Simon D McLaughlin ◽  
Omar D Faiz ◽  
Susan K Clark ◽  
...  
Keyword(s):  
Side Effects ◽  
Antibiotic Therapy ◽  
Antibiotic Use ◽  
Safety And Efficacy ◽  
Pouch Failure ◽  
Patient Reported ◽  
Long Term Follow Up ◽  
Term Maintenance

ObjectiveRestorative proctolectomy is considered the procedure of choice in patients with ulcerative colitis who have failed medical therapy. Chronic pouchitis occurs in 10%–15% of patients, which often require long-term antibiotics to alleviate symptoms. Safety and efficacy of long-term maintenance antibiotics for chronic pouchitis has yet to be established. We aimed to assess the long-term safety and efficacy of maintenance antibiotic therapy for chronic pouchitis.DesignThis was an observational study. We followed up patients who were diagnosed with chronic antibiotic-dependent pouchitis.SettingData were collected from our single specialist pouch centre.PatientsPatients with chronic antibiotic-dependent pouchitis who had been maintained on antibiotics continuously for at least 1 year with a least one follow-up visit.Main outcome measureDevelopment of pouch failure defined by the need for an ileostomy, patient-reported side effects of antibiotics and development of antibiotic resistance found on stool coliform testing.ResultsLong-term use of antibiotics achieve remission in 21% of patients over a median follow-up of 102 (range 9–125). Pouch failure in association with chronic pouchitis after a median follow-up of 8.5 years occurred in 18%. Side effects of long-term antibiotic use occurred in 28% of patients, with resistance to antibiotics from at least one stool sample occurring in 78% patients.ConclusionsAlthough the use of antibiotics in chronic pouchitis may be justified, the use of long-term antibiotics must be weighed against potential complications associated with pouchitis and antibiotics.

Sign in / Sign up

Export Citation Format

Share Document